GlaxoSmithKline is scrapping more than 30 drug development programs. The major cull of pipeline prospects will see GSK focus 80% of its R&D budget on the top candidates in four therapeutic areas and potentially exit the rare disease space.
{iframe}http://www.fiercebiotech.com/biotech/gsk-stops-development-30-pipeline-prospects-mulls-sale-rare-disease-unit-as-new-ceo{/iframe}